Z. Al-Kadhimi

发表

Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort

A. Deol, E. Waller, L. Lum, 2015, Bone Marrow Transplantation.

Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.

M. Kalos, S. Forman, M. Jensen, 2004, Blood cells, molecules & diseases.

Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

David D. Smith, S. Forman, M. Jensen, 2005, Blood.

Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.

A. Nademanee, A. Krishnan, G. Somlo, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

TargetedT-cell Therapy in Stage IVBreastCancer : A Phase I Clinical Trial

A. Thakur, D. Dizon, Qin Liu, 2015 .

Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial

A. Thakur, D. Dizon, Qin Liu, 2015, Clinical Cancer Research.

Summary of the Third Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

N. Munshi, P. Hari, M. Pasquini, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.

David D. Smith, G. McNamara, S. Forman, 2006, Blood.

Development and prospects for bispecific antibody-based therapeutics in cancer and other applications

L. Lum, Z. Al-Kadhimi, 2008, Expert opinion on drug discovery.

Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.

David D. Smith, S. Gillies, G. McNamara, 2007, Cancer research.

Enhanced antilymphoma efﬁcacy of CD19-redirected inﬂuenza MP1–speciﬁc CTLs by cotransfer of T cells modiﬁed to present inﬂuenza MP1

S. Forman, M. Jensen, S. Olivares, 2005 .

Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia.

J. Armitage, V. Bhatt, S. Holstein, 2022, Journal of geriatric oncology.

Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma

J. Abrams, A. Deol, J. Zonder, 2012, Journal of chemotherapy.

A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma

J. Abrams, A. Deol, L. Lum, 2010 .

Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma

J. Abrams, A. Deol, J. Zonder, 2013, Supportive Care in Cancer.

Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial

J. Abrams, L. Lum, V. Ratanatharathorn, 2012, Supportive Care in Cancer.

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer

M. Simon, A. Thakur, A. Deol, 2021, Journal for ImmunoTherapy of Cancer.

Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML

J. Abrams, A. Deol, L. Lum, 2013, Bone Marrow Transplantation.

Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients.

V. Bhatt, E. Lyden, L. Maness, 2019, Future oncology.

A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.

J. Abrams, A. Deol, J. Zonder, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?

C. Flowers, S. Lonial, Zhengjia Chen, 2016, Clinical lymphoma, myeloma & leukemia.

Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease.

L. Lum, V. Ratanatharathorn, M. Abidi, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HIV infection and antiphospholipid antibody: literature review and link to the antiphospholipid syndrome.

Z. Al-Kadhimi, J. Cervia, A. Hassoun, 2004, AIDS patient care and STDs.

PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients

E. Waller, G. Kunter, D. Jaye, 2017, PloS one.

Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.

L. Leong, P. Frankel, G. Somlo, 2009, Anticancer research.

Large pericardial effusion as a complication in adults undergoing SCT

M. Norkin, L. Lum, V. Ratanatharathorn, 2011, Bone Marrow Transplantation.

Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy.

J. Armitage, V. Bhatt, S. Holstein, 2020, Clinical lymphoma, myeloma & leukemia.

Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.

A. Thakur, A. Deol, J. Zonder, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease

J. Dipersio, H. Khoury, D. Roberts, 2018, Bone Marrow Transplantation.

Lambert–Eaton syndrome with large‐cell neuroendocrine carcinoma of the lung

C. Grommes, A. Alshekhlee, D. Preston, 2008, Muscle & nerve.

High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.

A. Deol, E. Waller, L. Lum, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.

S. Forman, A. Deol, L. Lum, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduce

N. Geller, P. Hari, D. Porter, 2019, The Lancet. Haematology.

Role of myeloid-derived suppressor cells in tumor recurrence

J. Talmadge, Z. Al-Kadhimi, Kathryn Cole, 2023, Cancer and Metastasis Reviews.

Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapy.

J. Vose, T. Fehniger, Z. Al-Kadhimi, 2022, International immunopharmacology.

Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.

M. Bar, J. Wagner, J. Sierra, 2021, Transplantation and cellular therapy.

Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.

A. Deol, L. Lum, V. Ratanatharathorn, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Enhancing siRNA effects in T cells for adoptive immunotherapy

K. Morris, J. Rossi, D. Castanotto, 2005, Hematology.

Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations.

M. Kharfan-Dabaja, M. Hamadani, T. Nishihori, 2016, Immunotherapy.

Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Kirk A Easley, N. Shenvi, H. Khoury, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention

A. Deol, E. Waller, L. Lum, 2017, Bone Marrow Transplantation.

Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL

J. Armitage, J. Vose, J. Talmadge, 2022, Bone Marrow Transplantation.

Highlights into historical and current immune interventions for cancer.

J. Talmadge, Z. Al-Kadhimi, Kathryn Cole, 2023, International immunopharmacology.

Prevention of graft versus host disease with Hematopoietic CellTransplantation with Reduced Intensity Conditioning—a comparison of threeprophylaxis regimens (tacrolimus/mycophenolate mofetil/cyclophosphamide,tacrolimus/methotrexate/bortezomib or tacrolimus/methotrexate/maraviroc) versustacrolimus/me

N. Geller, P. Hari, M. Pasquini, 2019 .

Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies

M. Angelopoulou, G. Somlo, S. Forman, 2004, Bone Marrow Transplantation.

Brain Amyloidoma With Cerebral Hemorrhage

A. Alshekhlee, Z. Al-Kadhimi, Roger Oghlakian, 2009, The Journal of the American Osteopathic Association.

High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment and Tolerability in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Th

M. Berger, P. Hari, K. van Besien, 2022, Transplantation and Cellular Therapy.

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

M. Berger, P. Hari, J. Pagel, 2021, Blood.

CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.

A. Thakur, A. Deol, Qin Liu, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors

Yun Yen, James H. Doroshow, Adam Mamelak, 2010, Cancer Chemotherapy and Pharmacology.

Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia.

V. Bhatt, V. Shostrom, L. Maness, 2020, Clinical lymphoma, myeloma & leukemia.

Effects of Distance From Academic Cancer Center on Overall Survival of Acute Myeloid Leukemia: Retrospective Analysis of Treated Patients.

V. Bhatt, E. Lyden, L. Maness, 2020, Clinical lymphoma, myeloma & leukemia.

Effects of Obesity on Overall Survival of Adults With Acute Myeloid Leukemia.

V. Bhatt, E. Lyden, L. Maness, 2019, Clinical lymphoma, myeloma & leukemia.

Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant

A. Deol, L. Lum, V. Ratanatharathorn, 2014, Journal of clinical apheresis.

Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia

V. Bhatt, E. Lyden, L. Maness, 2020, Leukemia & lymphoma.

Induction Of Anti-Myeloma Cellular and Humoral Immunity By Pre-Targeting Clonogenic Myeloma Cells Prior To Stem Cell Transplant With T Cells Armed With Anti-CD3 x Anti-CD20 Bispecific Antibody Leads To Transfer Of Cellular and Humoral Anti-Myeloma Immunity

A. Thakur, A. Deol, J. Zonder, 2013 .

Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors

C. Flowers, V. Master, J. Arora, 2017, Bone Marrow Transplantation.

The Missing LNK: Evolution from Cytosis to Chronic Myelomonocytic Leukemia in a Patient with Multiple Sclerosis and Germline SH2B3 Mutation

B. Dave, V. Bhatt, L. Maness, 2022, Case reports in genetics.

A phase II study of tacrolimus and thymoglobulin as graft‐versus‐host‐disease prophylaxis in related donor allogeneic hematopoietic cell transplantation

A. Deol, V. Ratanatharathorn, J. Uberti, 2018, American journal of hematology.

PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients

E. Waller, G. Kunter, D. Jaye, 2017, PloS one.

Tacrolimus Disposition in the Ascitic Fluid of a Bone Marrow Transplant Patient

D. Edwards, M. Abidi, J. Uberti, 2010, The Annals of pharmacotherapy.

J. Abrams, A. Deol, J. Zonder, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.